|
1
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Macor P and Tedesco F: Complement as
effector system in cancer immunotherapy. Immunol Lett. 111:6–13.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pawluczkowycz AW, Beurskens FJ, Beum PV,
Lindorfer MA, van de Winkel JG, Parren PW and Taylor RP: Binding of
submaximal C1q promotes complement-dependent cytotoxicity (CDC) of
B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab
(RTX): Considerably higher levels of CDC are induced by OFA than by
RTX. J Immunol. 183:749–758. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meyer S, Leusen JH and Boross P:
Regulation of complement and modulation of its activity in
monoclonal antibody therapy of cancer. MAbs. 6:1133–1144. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Szebeni J, Alving CR, Savay S, Barenholz
Y, Priev A, Danino D and Talmon Y: Formation of
complement-activating particles in aqueous solutions of Taxol:
Possible role in hypersensitivity reactions. Int Immunopharmacol.
1:721–735. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gilbert RD, Stanley LK, Fowler DJ, Angus
EM, Hardy SA and Goodship TH: Cisplatin-induced haemolytic uraemic
syndrome associated with a novel intronic mutation of CD46 treated
with eculizumab. Clin Kidney J. 6:421–425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spendlove I, Ramage JM, Bradley R, Harris
C and Durrant LG: Complement decay accelerating factor (DAF)/CD55
in cancer. Cancer Immunol Immunother. 55:987–995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li L, Spendlove I, Morgan J and Durrant
LG: CD55 is over-expressed in the tumour environment. Br J Cancer.
84:80–86. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Durrant LG, Doran M, Austin EB and Robins
RA: Induction of cellular immune responses by a murine monoclonal
anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed
on colorectal, gastric and ovarian human tumours. Int J Cancer.
61:62–66. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dho SH, Kim SY, Chung C, Cho EH, Lee SY,
Kim JY, Kim LK, Min SW, Lee J, Jung SH and Lim JC: Development of a
radionuclide-labeled monoclonal anti-CD55 antibody with theranostic
potential in pleural metastatic lung cancer. Sci Rep. 8:89602018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thorsteinsson L, O'Dowd GM, Harrington PM
and Johnson PM: The complement regulatory proteins CD46 and CD59,
but not CD55, are highly expressed by glandular epithelium of human
breast and colorectal tumour tissues. APMIS. 106:869–878. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marisa L, de Reyniès A, Duval A, Selves J,
Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D,
Ayadi M, et al: Gene expression classification of colon cancer into
molecular subtypes: Characterization, validation, and prognostic
value. PLoS Med. 10:e10014532013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Timmermann B, Kerick M, Roehr C, Fischer
A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig
J, et al: Somatic mutation profiles of MSI and MSS colorectal
cancer identified by whole exome next generation sequencing and
bioinformatics analysis. PLoS One. 5:e156612010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gustavsson B, Carlsson G, Machover D,
Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of
the evolution of systemic chemotherapy in the management of
colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Russo A, Maiolino S, Pagliara V, Ungaro F,
Tatangelo F, Leone A, Scalia G, Budillon A, Quaglia F and Russo G:
Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in
p53 null colon cancer cells through combined polymer nanoparticles.
Oncotarget. 7:79670–79687. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Modest DP, Neumann UP and Pratschke J:
FOLFOXIRI plus bevacizumab as conversion-therapy for liver
metastases in colorectal cancer: A necessity? Eur J Cancer.
73:71–73. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Launay M, Dahan L, Duval M, Rodallec A,
Milano G, Duluc M, Lacarelle B, Ciccolini J and Seitz JF: Beating
the odds: Efficacy and toxicity of dihydropyrimidine
dehydrogenase-driven adaptive dosing of 5-FU in patients with
digestive cancer. Br J Clin Pharmacol. 81:124–130. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bamford S, Dawson E, Forbes S, Clements J,
Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR
and Wooster R: The COSMIC (Catalogue of Somatic Mutations in
Cancer) database and website. Br J Cancer. 91:355–358. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shin G, Kang TW, Yang S, Baek SJ, Jeong YS
and Kim SY: GENT: Gene expression database of normal and tumor
tissues. Cancer Inform. 10:149–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HY: Analysis of variance (ANOVA)
comparing means of more than two groups. Restor Dent Endod.
39:74–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakagawa M, Mizuno M, Kawada M, Uesu T,
Nasu J, Takeuchi K, Okada H, Endo Y, Fujita T and Tsuji T:
Polymorphic expression of decay-accelerating factor in human
colorectal cancer. J Gastroenterol Hepatol. 16:184–189. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koretz K, Brüderlein S, Henne C and Möller
P: Decay-accelerating factor (DAF, CD55) in normal colorectal
mucosa, adenomas and carcinomas. Br J Cancer. 66:810–814. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niehans GA, Cherwitz DL, Staley NA, Knapp
DJ and Dalmasso AP: Human carcinomas variably express the
complement inhibitory proteins CD46 (membrane cofactor protein),
CD55 (decay-accelerating factor), and CD59 (protectin). Am J
Pathol. 149:129–142. 1996.PubMed/NCBI
|
|
27
|
Liu J, Miwa T, Hilliard B, Chen Y, Lambris
JD, Wells AD and Song WC: The complement inhibitory protein DAF
(CD55) suppresses T cell immunity in vivo. J Exp Med. 201:567–577.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mikesch JH, Schier K, Roetger A, Simon R,
Buerger H and Brandt B: The expression and action of
decay-accelerating factor (CD55) in human malignancies and cancer
therapy. Cell Oncol. 28:223–232. 2006.PubMed/NCBI
|
|
29
|
Zhao WP, Zhu B, Duan YZ and Chen ZT:
Neutralization of complement regulatory proteins CD55 and CD59
augments therapeutic effect of herceptin against lung carcinoma
cells. Oncol Rep. 21:1405–1411. 2009.PubMed/NCBI
|
|
30
|
Boire A, Zou Y, Shieh J, Macalinao DG,
Pentsova E and Massagué J: Complement component 3 adapts the
cerebrospinal fluid for leptomeningeal metastasis. Cell.
168:1101.e13–1113.e13. 2017. View Article : Google Scholar
|
|
31
|
Kir S, White JP, Kleiner S, Kazak L, Cohen
P, Baracos VE and Spiegelman BM: Tumour-derived PTH-related protein
triggers adipose tissue browning and cancer cachexia. Nature.
513:100–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Morgan J, Spendlove I and Durrant LG: The
role of CD55 in protecting the tumour environment from complement
attack. Tissue Antigens. 60:213–223. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Egan ES, Jiang RH, Moechtar MA, Barteneva
NS, Weekes MP, Nobre LV, Gygi SP, Paulo JA, Frantzreb C, Tani Y, et
al: Malaria. A forward genetic screen identifies erythrocyte CD55
as essential for Plasmodium falciparum invasion. Science.
348:711–714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ozen A, Comrie WA, Ardy RC, Domínguez
Conde C, Dalgic B, Beser ÖF, Morawski AR, Karakoc-Aydiner E, Tutar
E, Baris S, et al: CD55 deficiency, early-onset protein-losing
enteropathy, and thrombosis. N Engl J Med. 377:52–61. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Visser L, de Vos AF, Hamann J, Melief MJ,
van Meurs M, van Lier RA, Laman JD and Hintzen RQ: Expression of
the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple
sclerosis. J Neuroimmunol. 132:156–163. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hillmen P, Young NS, Schubert J, Brodsky
RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, et al:
The complement inhibitor eculizumab in paroxysmal nocturnal
hemoglobinuria. N Engl J Med. 355:1233–1243. 2006. View Article : Google Scholar : PubMed/NCBI
|
